GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » PE Ratio

Cannara Biotech (TSXV:LOVE) PE Ratio : 12.00 (As of Dec. 14, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-12-14), Cannara Biotech's share price is C$0.72. Cannara Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Aug. 2024 was C$0.06. Therefore, Cannara Biotech's PE Ratio for today is 12.00.

During the past 7 years, Cannara Biotech's highest PE Ratio was 29.38. The lowest was 8.89. And the median was 14.00.

Cannara Biotech's EPS (Diluted) for the three months ended in Aug. 2024 was C$0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Aug. 2024 was C$0.06.

As of today (2024-12-14), Cannara Biotech's share price is C$0.72. Cannara Biotech's EPS without NRI for the trailing twelve months (TTM) ended in Aug. 2024 was C$0.04. Therefore, Cannara Biotech's PE Ratio without NRI ratio for today is 17.14.

During the past 7 years, Cannara Biotech's highest PE Ratio without NRI was 32.64. The lowest was 8.79. And the median was 15.74.

Cannara Biotech's EPS without NRI for the three months ended in Aug. 2024 was C$0.06. Its EPS without NRI for the trailing twelve months (TTM) ended in Aug. 2024 was C$0.04.

During the past 12 months, Cannara Biotech's average EPS without NRI Growth Rate was -35.80% per year.

During the past 7 years, Cannara Biotech's highest 3-Year average EPS without NRI Growth Rate was -48.40% per year. The lowest was -48.40% per year. And the median was -48.40% per year.

Cannara Biotech's EPS (Basic) for the three months ended in Aug. 2024 was C$0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Aug. 2024 was C$0.06.

Back to Basics: PE Ratio


Cannara Biotech PE Ratio Historical Data

The historical data trend for Cannara Biotech's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech PE Ratio Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
PE Ratio
Get a 7-Day Free Trial At Loss At Loss 45.00 12.50 9.71

Cannara Biotech Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.50 9.00 16.33 14.40 9.71

Competitive Comparison of Cannara Biotech's PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's PE Ratio distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's PE Ratio falls into.



Cannara Biotech PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Cannara Biotech's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=0.72/0.060
=12

Cannara Biotech's Share Price of today is C$0.72.
Cannara Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.06.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Cannara Biotech  (TSXV:LOVE) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Cannara Biotech PE Ratio Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
Executives
Nicholas Sosiak Senior Officer
Olymbec Investments Inc. 10% Security Holder
Derek Elan Stern Director
Donald John Olds Director
Scott Carroll Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Zohar Krivorot Director, Senior Officer
Brian Sherman Senior Officer
Avi Krivorot Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Lennie Ryer Senior Officer
Jack M. Kay Director
Donal Carroll Director or Senior Officer of 10% Security Holder